Kamada (NASDAQ:KMDA) Stock Crosses Above Fifty Day Moving Average – Should You Sell?

Kamada Ltd. (NASDAQ:KMDA)’s stock price crossed above its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $6.96 and traded as high as $7.30. Kamada shares last traded at $7.24, with a volume of 64,147 shares changing hands.

Analysts Set New Price Targets

KMDA has been the topic of several research reports. Weiss Ratings reiterated a “buy (b-)” rating on shares of Kamada in a research note on Wednesday, October 8th. Wall Street Zen upgraded shares of Kamada from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 13th. Finally, HC Wainwright raised their price objective on Kamada from $11.00 to $13.00 and gave the company a “buy” rating in a research note on Tuesday, December 9th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $14.00.

Kamada Price Performance

The firm has a market capitalization of $416.37 million, a price-to-earnings ratio of 20.11, a price-to-earnings-growth ratio of 0.61 and a beta of 0.93. The business has a 50 day moving average of $6.96 and a 200 day moving average of $7.12.

Kamada (NASDAQ:KMDA) last issued its earnings results on Monday, November 10th. The biotechnology company reported $0.09 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.01). Kamada had a net margin of 11.70% and a return on equity of 7.89%. The business had revenue of $47.01 million for the quarter, compared to analyst estimates of $154.21 million. On average, sell-side analysts forecast that Kamada Ltd. will post 0.23 EPS for the current fiscal year.

Hedge Funds Weigh In On Kamada

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Trexquant Investment LP bought a new stake in shares of Kamada during the first quarter worth $82,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Kamada during the first quarter worth $206,000. NewEdge Advisors LLC lifted its holdings in Kamada by 119.9% during the first quarter. NewEdge Advisors LLC now owns 51,661 shares of the biotechnology company’s stock worth $341,000 after acquiring an additional 28,165 shares in the last quarter. Goldman Sachs Group Inc. bought a new stake in Kamada during the 1st quarter worth approximately $497,000. Finally, Jane Street Group LLC acquired a new stake in Kamada during the 1st quarter worth approximately $582,000. 20.38% of the stock is currently owned by institutional investors and hedge funds.

Kamada Company Profile

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma‐derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha‐1 antitrypsin augmentation therapy approved by the U.S.